Ochre Bio

Ochre Bio is a private, preclinical-stage biotech pioneering a data-driven approach to liver disease. The company has built a unique 'Human Discovery Platform' combining extensive human liver datasets, AI-driven causal prediction, and validation in sophisticated human ex vivo models like perfused livers. This integrated strategy, coupled with an in-house RNA therapeutic manufacturing capability, aims to rapidly translate novel targets into clinical candidates, as evidenced by a significant partnership with GSK and a pipeline targeting fibrosis and cirrhosis.

Integrated platform combining: 1) Human Discovery Platform (AI analysis of proprietary human liver genomic and gene perturbation data), 2) Human Validation Platform (ex vivo validation using perfused human livers, tissue slices), and 3) an in-house RNA therapeutic manufacturing platform.

Ochre operates in the highly competitive chronic liver disease space, competing with large pharma (e.g., Novo Nordisk, Madrigal, Boehringer Ingelheim) and other biotechs pursuing small molecules, FXR agonists, and other modalities for MASH/MASLD and fibrosis. Its differentiation lies in its human-data-first AI platform and use of sophisticated human ex vivo validation models, aiming to de-risk target selection.